Literature DB >> 28789840

Cyclophilin inhibitor NIM811 ameliorates experimental allergic encephalomyelitis.

Zi L Huang1, Darshan Pandya1, Daisy K Banta1, Maryam S Ansari1, Unsong Oh2.   

Abstract

Cyclophilins have diverse functions that may affect the course of central nervous system (CNS) inflammatory disorders. Anti-inflammatory and neuroprotective mechanisms may be targeted by inhibition of cyclophilin A-dependent and cyclophilin D-dependent functions, respectively. We tested the effect of cyclophilin inhibition on CNS inflammation by administering N-methyl-4-isoleucine-cyclosporin (NIM811) to mice undergoing experimental allergic encephalomyelitis (EAE). Treatment with NIM811 resulted in significant reduction of EAE clinical severity. Analysis of mitochondrial calcium retention capacity and the course of EAE in cyclophilin D knockout mice indicated that the effect of NIM811 on EAE was not entirely cyclophilin D-dependent. NIM811-treated EAE animals showed reduction in interleukin-2 expression and reduction in CNS inflammatory infiltrates. These results indicate that anti-inflammatory rather than neuroprotective mechanisms associated with cyclophilins are likely involved in the mechanism of NIM811 in EAE.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Central nervous system; Cyclophilin; Experimental allergic encephalomyelitis; Inflammation; Leucocyte; Mitochondria

Mesh:

Substances:

Year:  2017        PMID: 28789840     DOI: 10.1016/j.jneuroim.2017.07.016

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  2 in total

1.  The contribution of cyclophilin A to immune-mediated central nervous system inflammation.

Authors:  Vahnee Garimella; Julie Secor McVoy; Unsong Oh
Journal:  J Neuroimmunol       Date:  2019-11-22       Impact factor: 3.478

2.  A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.

Authors:  Joseph Kuo; Michael Bobardt; Udayan Chatterji; Patrick R Mayo; Daniel J Trepanier; Robert T Foster; Philippe Gallay; Daren R Ure
Journal:  J Pharmacol Exp Ther       Date:  2019-08-12       Impact factor: 4.030

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.